检索结果-南通市图书馆

Increased Incidence of Severe Adverse Events in Non-Small Cell Lung Cancer Patients with Previous tuberculosis Episode Treated with PD-1 Inhibitors

在线全文

学校读者我要写书评

暂无评论

Biomedical and Environmental Sciences 2024年第7期37卷 785-789页

作者： Hui Zhang Jinfeng Yuan Yuanyuan Xu Mengjie Yang Jialin Lyu Xinjie Yang Shuyan Sheng Zhe Qian Qunhui Wang Yu Pang Ying Hu Department of Medical Oncology Beijing Chest HospitalCapital Medical University&Beijing Tuberculosis and Thoracic Tumor Research InstituteBeijing 101149China Department of Bacteriology and Immunology Beijing Key Laboratory on Drug-Resistant Tuberculosis ResearchBeijing Chest HospitalCapital Medical University/Beijing Tuberculosis&Thoracic Tumor Research InstituteBeijing 101149China Chinese Center for Disease Control and Prevention Beijing 102206China

Lung cancer is the top cause of cancer deaths *** in immune checkpoint inhibitors(ICIs)have transformed cancer treatment,but their use in lung cancer has led to more side *** study examined if past pulmonary tuberculosis(TB)affects ICIs’effectiveness and safety in lung cancer *** reviewed lung cancer patients treated with ICIs at beijing Chest Hospital from January 2.19 to August 2.2..

关键词： Lung lung Cancer

Recent progresses of exosome-liposome fusions in drug delivery

在线全文

学校读者我要写书评

暂无评论

Chinese Chemical Letters 2024年第2期35卷 107-117页

作者： Lulu Zheng Bo Hu Deyao Zhao Wenjing Liu Qing Liu Yuanyu Huang Shaobo Ruan School of Life Science Advanced Research Institute of Multidisciplinary ScienceSchool of Medical TechnologyKey Laboratory of Molecular Medicine and BiotherapyKey Laboratory of Medical Molecule Science and Pharmaceutics EngineeringBeijing Institute of TechnologyBeijing 100081China Department of Radiation Oncology The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450000China beijing Key Laboratory of Drug Resistance tuberculosis {2. Beijing Tuberculosis and Thoracic Tumor Research Instituteand Beijing Chest HospitalCapital Medical UniversityBeijing 101149China

Exosomes are membrane-bound nanoscale extracellular vesicles,which produced by almost all *** to the excellent biocompatibility,long circulation time as well as low immunogenicity,exosomes as naturally-derived drug delivery carriers have experienced explosive growth over the past ***,issues such as insufficient loading efficiency,heterogeneous delivery efficiency,uncontrollable targeting ability,and low production limit their wide ***,the emerging exosome-liposome fusion strategy has become a potential approach to solve such ***,this review mainly focuses on the currently developed exosome-liposome fusion strategy and their application in drug delivery as well as disease *** review aims to shed light on the advantages of fusion strategy in drug delivery and provides a better understanding for more rational *** current challenge and future perspective regarding their clinical translation and application will also be discussed.

关键词： Exosome Liposome Membrane fusion Drug delivery Disease treatment

Prognostic role of C-reactive protein to albumin ratio in lung cancer:An updated systematic review and meta-analysis

在线全文

学校读者我要写书评

暂无评论

Chronic Diseases and Translational Medicine 2024年第1期10卷 31-39页

作者： Zhendong Lu Siyun Fu Wei Li Xiang Gao Jinghui Wang Department of Medical Oncology Beijing Tuberculosis and Thoracic Tumor Research InstituteBeijing Chest HospitalCapital Medical UniversityBeijingChina Cancer research Center Beijing Chest HospitalBeijing Tuberculosis and Thoracic Tumor Research InstituteCapital Medical UniversityBeijingChina

Background: C-reactive protein to albumin ratio(CRP/Alb ratio,CAR)has been suggested as a potential prognostic biomarker in lung *** updated systematic review and meta-analysis aimed to assess the association between CAR and lung cancer prognosis in current ***: A systematic search of databases was conducted to identify relevant studies published up to April *** hazard ratios(HRs)and 95%confidence intervals(CIs)were calculated to assess the association between CAR and overall survival(OS)and progression-free survival(PFS)and recurrence-free survival(RF)in lung cancer ***: This meta-analysis includes 16 studies with a total of 5337 patients,indicating a significant association between higher CAR and poorer OS,PFS,and RFS in lung cancer patients,with a pooled HR of 1.78(95%CI=1.60-1.99),1.57(95%CI=1.36-1.80),and 1.97(95%CI=1.40-2.77),***: This updated meta-analysis provides evidence for the potential prognostic role of CAR in lung cancer,suggesting its utility as an effective and noninvasive biomarker for identifying high-risk patients and informing treatment decisions in a cost-effective ***,further large-scale studies will be necessary to establish the optimal cut-off value for CAR in lung cancer and confirm the present findings.

关键词： C-reactive protein to albumin ratio inflammation:biomarker lung cancer prognosis

Ki-67 Change in Anthracyline-containing Neoadjuvant Chemotherapy Response in Breast Cancer

在线全文

学校读者我要写书评

暂无评论

Current Medical Science 2024年第1期44卷 156-167页

作者： Zi-guo YANG Le-hao REN Feng WANG Pi-lin WANG Wen-yan WANG Shu-ye LIN Department of General Surgery Beijing Tiantan HospitalCapital Medical UniversityBeijing 100070China Department of Critical Care Medicine Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022China Cancer research Center Beijing Chest HospitalCapital Medical University/Beijing Tuberculosis and Thoracic Tumor Research InstituteBeijing 101149China

Objective Anthracycline-containing regimens are irreplaceable in neoadjuvant chemotherapy(NAC)for breast cancer(BC)at ***,30% of early breast cancer(EBC)patients are resistant to anthracycline-containing chemotherapy,leading to poor prognosis and higher ***-67 is associated with the prognosis and response to therapy,and it changes after *** A total of 105 BC patients who received anthracycline-containing NAC were ***,the optimal model of Ki-67 was selected,and its predictive efficacy was ***(IHC)was used to determine the estrogen receptor(ER),progesterone receptor(PR),and human epidermal growth factor receptor 2.HER-2.status and Ki-67 *** in situ hybridization(FISH)was used to verify the HER-2.when the IHC score was 2..Results The post-NAC Ki67 level after treatment with anthracycline drugs was lower than pre-NAC Ki-67(19.6%±2..3%vs.45.6%±2..1%,P2.vs.0.0%,P=0.068),and a higher overall response rate(ORR)(73.6%vs.2..8%,P2.)and 0.755(0.655-0.855),respectively,while the AUC for ΔKi-67% on pCR and ORR was 0.857(0.742.0.972.and 0.72.(0.618-0.82.),*** logistic regression model 1 revealed thatΔKi-67 was an independent predictor for both pCR[odds ratio(OR)=61.030,95% confidence interval(CI)=4.709-790.965;P=0.002.and ORR(OR=10.001,95%CI:3.044-32.858;P2.revealed thatΔKi-67%was also an independent predictor for both pCR(OR=408.92.,95%CI=8.908-18771.2.4;P=0.002.and ORR(OR=5.419,95%CI=1.842.15.943;P=0.002..Conclusions The present study results suggest thatΔKi67 andΔKi67%are candidate predictor

关键词： breast cancer change in Ki-67 neoadjuvant chemotherapy anthracycline,response

Celecoxib enhances the response of tumor cells to cisplatin through upregulating PUMA in non–small cell lung cancer carrying wild-type p53

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Oncology and Translational Medicine 2024年第2期10卷 79-86页

作者： Yuxuan Xiao Ziyu Wang Meng Gu Jinjing Tan Weiying Li Cancer research Center Beijing Chest HospitalCapital Medical UniversityBeijing Tuberculosis and Thoracic Tumor Research InstituteBeijingChina

Celecoxib,a cyclooxygenase-2.inhibitor,can enhance the efficacy of chemotherapy;however,its effect seems *** this study,we investigated whether celecoxib would increase the antiproliferative effects of cisplatin in human lung cancer *** data demonstrated the synergistic effects of celecoxib with cisplatin in wild-type p53 cells and their antagonistic effects inmutated or deleted p53 *** indices of 0.82.to 0.93 reflected a synergistic effect between celecoxib and cisplatin in lung cancer cells with wild-type *** indices of 1.63 to 3.00 reflected antagonism between celecoxib and cisplatin in lung cancer cells with mutated or deleted *** with that in cells with mutated or deleted p53,apoptosis significantly increased with the addition of celecoxib and cisplatin in wild-type p53 cells(Ptumor growth in wild-type p53 groups and not in mutated or deleted p53 *** addition,celecoxib promoted p53 translocation into the nucleus and upregulated active p53 expression in wild-type p53 *** combined with cisplatin upregulated PUMA(PUMA is a downstream gene of p53)after active p53 increased in wild-type p53 *** summary,the combination of celecoxib and cisplatin demonstrates clear synergistic effects in wild-type p53 cells and antagonistic effects inmutated or deleted p53 *** synergistic effect was achieved by apoptosis,induced by upregulating *** results will provide a new treatment strategy for patients carrying wild-type p53,insensitive to cisplatin.

关键词： p53 Celecoxib Cisplatin Non-small cell lung cancer PUMA

Unveiling the secrets of gastrointestinal mucous adenocarcinoma survival after surgery with artificial intelligence:A population-based study

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Oncology 2024年第6期16卷 2404-2418页

作者： Jie Song Xiang-Xiu Yan Fang-Liang Zhang Yong-Yi Lei Zi-Yin Ke Fang Li Kai Zhang Yu-Qi He Wei Li Chao Li Yuan-Ming Pan Department of Gastroenterology Dongying People’s HospitalDongying Hospital of Shandong Provincial Hospital GroupDongying 257000Shandong ProvinceChina Gastrointestinal Surgery Department Suining Central HospitalSuining 629000Sichuan ProvinceChina Obstetrical Department Suining Central HospitalSuining 629000Sichuan ProvinceChina School of Medicine Shenzhen Campus of Sun Yat-sen UniversityShenzhen 518107Guangdong ProvinceChina Department of Pathology Aerospace Center HospitalPeking University Aerospace School of Clinical MedicineBeijing 100049China General Department Beijing Chest HospitalCapital Medical University/Beijing Tuberculosis and Thoracic Tumor Research InstituteBeijing 101149China Department of Gastroenterology Beijing Chest HospitalCapital Medical University/Beijing Tuberculosis and Thoracic Tumor Research InstituteBeijing 101149China Department of thoracic Surgery Sichuan Academy of Medical Sciences and Sichuan Provincial People’s HospitalUniversity of Electronic Science and Technology of ChinaChengdu 610072Sichuan ProvinceChina Department of Gastroenterology Aerospace Center HospitalPeking University Aerospace School of Clinical MedicineBeijing 100049China Cancer research Center Beijing Chest HospitalCapital Medical University/Beijing Tuberculosis and Thoracic Tumor Research InstituteBeijing 101149China

BACKGROUND research on gastrointestinal mucosal adenocarcinoma(GMA)is limited and controversial,and there is no reference tool for predicting postoperative *** To investigate the prognosis of GMA and develop predictive *** From the Surveillance,Epidemiology,and End Results database,we collected clinical information on patients with *** random sampling,the patients were divided into the discovery(70%of the total,for model training),validation(2.%,for model evaluation),and completely blind test cohorts(10%,for further model evaluation).The main assessment metric was the area under the receiver operating characteristic curve(AUC).All collected clinical features were used for Cox proportional hazard regression analysis to determine factors influencing GMA’s *** This model had an AUC of 0.7433[95% confidence intervals(95%CI):0.742.-0.7442.in the discovery cohort,0.72.4(GMA:0.72.4-0.72.4)in the validation cohort,and 0.7388(95%CI:0.7378-0.7398)in the test *** packaged it into Windows software for doctors’use and uploaded *** gastric adenocarcinoma had the worst prognosis,and these were protective factors of GMA:Regional nodes examined[hazard ratio(HR):0.98,95%CI:0.97-0.98,P2.95%CI:0.58-0.66,P<0.001).CONCLUSION The deep learning-based tool developed can accurately predict the overall survival of patients with GMA *** surgery,chemotherapy,and adequate lymph node dissection during surgery can improve patient outcomes.

关键词： Deep learning Gastrointestinal mucous adenocarcinoma Overall survival Surgery Clinical tool

Toward tuberculosis elimination by understanding epidemiologic characteristics and risk factors in Hainan Province, China

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Infectious Diseases of Poverty 2024年第1期13卷 107-108页

作者： Changqiang Zhou Tao Li Jian Du Dapeng Yin Xiujun Li Shixue Li Department of Biostatistics School of Public Health Cheeloo College of Medicine Shandong University Jinan People’s Republic of China National Center for tuberculosis Control and Prevention Chinese Center for Disease Control and Prevention Beijing People’s Republic of China Clinical Center On TB Control Beijing Chest Hospital Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute Beijing People’s Republic of China Hainan Center for Disease Control and Prevention Haikou People’s Republic of China research Center for tuberculosis Control Shandong University Jinan People’s Republic of China

Background The disease burden of tuberculosis(TB)was heavy in Hainan Province,China,and the information on transmission patterns was limited with few *** atudy aims to further explore the epidemiological charac-teristics and influencing factors of TB in Hainan Province,and thereby contribute valuable scientific evidences for TB elimination in Hainan *** The TB notification data in Hainan Province from 2.13 to 2.2. were collected from the Chinese National Disease Control Information System tuberculosis Surveillance System,along with socio-economic *** spatial-temporal and population distributions were analyzed,and spatial autocorrelation analysis was conducted to explore TB notification rate *** addition,the epidemiological characteristics of the cases among in-country migrants were described,and the delay pattern in seeking medical care was ***,a geographically and tem-porally weighted regression(GTWR)model was adopted to analyze the relationship between TB notification rate and socio-economic *** tailored control suggestions in different regions for TB elimination was provided by understanding epidemiological characteristics and risk factors obtained by *** From 2.13 to 2.2.,64,042.cases of TB were notified in Hainan *** estimated annual percent-age change of TB notification rate in Hainan Province from 2.13 to 2.2. was-6.88%[95%confidence interval(CI):-5.30%,-3.69%],with higher rates in central and southern *** majority of patients were males(76.33%)and farmers(67.80%).Cases among in-country migrants primarily originated from Sichuan(369 cases),Heilongjiang(2.7 cases),Hunan(2.6 cases),Guangdong(174 cases),and Guangxi(139 cases),accounting for 53%.The majority(98.83%)of TB cases were notified through passive case finding approaches,with delay in seeking *** GTWR analysis showed that gross domestic product per capita,the number of medical institutions and health personnel

关键词： tuberculosis Elimination Hainan Province China Epidemiological characteristics Geographically Temporally weighted regression

Targeting lncRNA16 by GalNAc-siRNA conjugates facilitates chemotherapeutic sensibilization via the HBB/NDUFAF5/ROS pathway

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Science China(Life Sciences) 2024年第4期67卷 663-679页

作者： Yanfang Liu Yan Wang Bing Liu Wenzhong Liu Yuanyuan Ma Yiren Cao Shi Yan Panpan Zhang Lixin Zhou Qimin Zhan Nan Wu Key Laboratory of Carcinogenesis and Translational research(Ministry of Education/beijing) Department of Thoracic Surgery IIPeking University Cancer Hospital and InstituteBeijing 100142China Key Laboratory of Carcinogenesis and Translational research(Ministry of Education/beijing) Laboratory of Molecular OncologyPeking University Cancer Hospital and InstituteBeijing 100142China Key Laboratory of Carcinogenesis and Translational research(Ministry of Education/beijing) Department of Thoracic Oncology IIPeking University Cancer Hospital and InstituteBeijing 100142China Key Laboratory of Carcinogenesis and Translational research(Ministry of Education) Department of PathologyPeking University Cancer Hospital and InstituteBeijing 100142China Peking University International Cancer institute Beijing 100191China institute of Cancer research Shenzhen Bay LaboratoryShenzhen 518132China

Chemoresistance is a significant barrier to effective cancer *** mechanisms for chemoresistance include reactive oxygen species(ROS)accumulation and expression of chemoresistance-promoting ***,we report a novel function of lncRNA16 in the inhibition of ROS generation and the progression of *** analyzing the serum levels of lncRNA16 in a cohort of 35 patients with non-small cell lung cancer(NSCLC)and paired serum samples pre-and post-treatment from 10 NSCLC patients receiving neoadjuvant platinum-based chemotherapy,performing immunohistochemistry(IHC)assays on 188 NSCLC tumor samples,using comprehensive identification of RNA-binding proteins by mass spectrometry(ChIRP-MS)assays,as well as RNA immunoprecipitation(RIP)and RNA pull-down analyses,we discovered that patients with increased serum levels of lncRNA16 exhibited a poor response to platinum-based *** expression of hemoglobin subunit beta(HBB)and NDUFAF5 significantly increases with the development of ***16 binds to HBB and promotes HBB accumulation by inhibiting ***16 can also inhibit ROS generation via the HBB/NDUFAF5 axis and function as a scaffold to facilitate the colocalization of HBB and NDUFAF5 in the ***,preclinical studies in mouse models of chemo-resistant NSCLC have suggested that lncRNA16 targeting by trivalent N-acetylgalactosamine(GalNAc)-conjugated siRNA restores chemosensitivity and results in tumor growth inhibition with no detectable toxicity in ***,lncRNA16 is a promising therapeutic target for overcoming chemoresistance,and the combination of first-line platinum-based chemotherapy with lncRNA16 intervention can substantially enhance anti-tumor efficacy.

关键词： chemoresistance lncRNARNA interference ROs chemosensitizer

Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer patients with epidermal growth factor receptor 2.L858R mutation:A multicenter,case-series study in China

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer research 2024年第4期36卷 398-409页

作者： Shouzheng Wang Jiayu Liu Yan Wang Ying Hu Ziling Liu Yu Yao Li Liang Yutao Liu Lin Wang Junling Li Puyuan Xing Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/CancerHospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Medical Oncology Beijing Chest HospitalCapital Medical UniversityBeijing Tuberculosis and Thoracic Tumor Research InstituteBeijing 101149China Cancer Center the First Hospital of Jilin UniversityChangchun 130021China Department of Medical Oncology the First Affiliated Hospital of Xi’an Jiaotong UniversityXi’an 710061China Department of Medical Oncology and Radiation Sickness Peking University Third HospitalBeijing 100191China

Objective:To provide real-world evidence for the application of first-line dacomitinib treatment for epidermal growth factor receptor(EGFR)2.L858R mutant non-small cell lung cancer(NSCLC)patients in China and to explore the factors influencing the efficacy and ***:A longitudinal,consecutive case-series,multicenter study with mixed prospective and retrospective data was *** primary endpoint was progression-free survival(PFS),and the secondary endpoints included duration of treatment(DOT),overall survival(OS),objective response rate(ORR),disease control rate(DCR)and ***:A total of 155 EGFR 2.L858R mutant patients treated with first-line dacomitinib were *** median follow-up time for these patients was 2..4 *** 134 patients with evaluable lesions,the ORR was 70.9%and the DCR was 96.3%.The median PFS was 16.3[95%confidence interval(95%CI),13.7−18.9]*** Cox regression analysis suggested that the baseline brain metastasis(BM)status[with *** BM:hazard ratio(HR),1.331;95%CI,0.72.−2.458;P=0.361]and initial doses(45 mg vs.30 mg:HR,0.837;95%CI,0.42.−1.641;P=0.604)did not significantly affect the median *** median DOT was 2..0(95%CI,17.5−2..6)months and the median OS was not *** tests were performed in 64 patients after progression,among whom 2.(45.3%)patients developed the EGFR 2.T790M *** addition,among the 46 patients who discontinued dacomitinib treatment after progression,31(67.4%)patients received subsequent third-generation EGFR-tyrosine kinase *** most common grade 3−4 adverse events were rash(10.4%),diarrhea(9.1%),stomatitis(7.1%)and paronychia(4.5%).The incidence of grade 3−4 rash was significantly higher in the 45 mg group than that in the 30 mg group(2..9%vs.7.5%,P=0.042..Conclusions:First-line dacomitinib treatment demonstrated promising efficacy and tolerable adverse events among EGFR 2.L858R mutant NSCLC patients in China.

关键词： Epidermal growth factor receptor molecular targeted therapy non-small cell lung cancer safety treatment efficacy